Kodiak Sciences Inc Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for KOD, updated each market day.
KOD AI Sentiment
AI predicts Kodiak Sciences Inc Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Kodiak Sciences Inc Common Stock
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Sector
Exchange
Market Cap
$2,619,875,773
Cap Tier
Employees
124
Headquarters
PALO ALTO, CA
Listed Since
Oct. 4, 2018
Website
KOD Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
KOD Volatility
Kodiak Sciences Inc Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
